Arbutus Biopharma Stock Price. Everything You Need To Know About The Arbutus Biopharma Stock!
Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 96 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, an oral capsid inhibitor, an oral programmed death-ligand-1 (PD-L1) inhibitor, and an oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is also having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses, including SARS-CoV-2.
Arbutus Biopharma Stock Price. Everything You Need To Know About The Arbutus Biopharma Stock! performance
- Employees 96
- Company HQ Warminster
- Website https://www.arbutusbio.com/
- ABUS Asset Type Common Stock
- ABUS Market Capitalization 484.1M
- Earnings Per Share -0.44
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Arbutus Biopharma is a leading biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies for viral diseases. With a wide range of groundbreaking research, Arbutus is revolutionizing the medical field, especially in the treatment of Hepatitis B. For retail investors from Malaysia, Thailand, Indonesia, and Vietnam, investing in Arbutus Biopharma can offer immense opportunities for growth and financial success. As a trusted investment platform, Zorion provides retail investors with valuable insights and recommendations to make informed decisions about their investment in Arbutus. With access to comprehensive resources and educational materials, investors can further enhance their knowledge about Arbutus Biopharma and the biopharmaceutical industry. Investing in Arbutus Biopharma from Malaysia, Thailand, Indonesia, and Vietnam has never been easier. Zorion empowers retail investors by offering simplified investment processes and easy access to real US stocks and Pre-IPO companies like Arbutus. Join Zorion today and discover the potential of investing in Arbutus Biopharma for your financial future.
